Ronald DePinho, the newly promoted boss of the University of Texas M.D. Anderson Cancer Center, declared that he hopes to discover new treatments for tumors under his leadership and that the chairmanship becomes meaningless if it is not successful. “I will not fail,” Ronald DePinho said. The doctor, who just moved from Harvard Medical School in Boston in September, is clearly confident. Ronald DePinho is one of the fund-raisers for the M.D. Anderson Cancer Center’s “Legends of Life Forum” in San Antonio, an in-depth discussion that includes Tom Johnson, a former CNN (formerly of the U.S. network CNN), in addition to veteran journalists Cokie Roberts and Sam Donaldson. He is the former CEO of CNN and has raised nearly$200,000 for the Center. Using light-hearted language such as “kicking tumor butt,” DePinho told us that “the new science and technology of the future can seal cancer in the dustbin of history. “There has never been a better opportunity to end the fear that tumors have brought to humanity,” said Ronald DePinho in a previous press conference, “which would have been unthinkable a decade ago. DePinho said the health care reform bill has its merits, such as its coverage of 47 million Americans, but he also said it will not be an effective solution to the nation’s health care crisis. “As we age, our bodies are at risk for Alzheimer’s disease, tumors and diseases of the elderly, so the new legislation doesn’t make a lot of sense,” he explained. This is a preventive measure. Roberts and Donaldson also said in a news release that they hope more programs that have not yet been passed in law will be enacted to draw attention to health care reform in the United States. “My guess is that the Supreme Court will decide that this legislation is constitutional, and I predict that it will eventually pass,” Donaldson said, “and if I’m wrong, then unfortunately we’ll be back to square one. Donaldson, who is still reveling in the M.D. Anderson Cancer Center’s Monday announcement of a guarantee for the “New Oncology Drug Creation Program,” analyzed the similarities between this new “applied cancer treatment technology” and The similarity between this new “applied cancer treatment technology” and “automated manufacturing”. “The current direction [of oncology research] is now evolving into something like an industrial assembly line, where, for example, a windshield is produced in one factory and shipped as parts to another factory, which then assembles it into a car, or not at all,” he said. We want to eliminate those chance factors in the development of new antineoplastic drugs. He said the MD Anderson Center can collaborate on a variety of research analyses, such as finding potential targeted therapeutic sites and then conducting clinical trials, rather than just being limited to the Houston campus. “We are able to do very intensive research collaborations with many institutes around the world,” he said, “and for that matter, we have a responsibility to work with researchers everywhere, such as in San Antonio, where we have collaborated extensively on a breast cancer project. “